BIOEQUIVALENCE OF FIXED DOSE COMBINATION (FDC) TABLETS OF LINAGLIPTIN/METFORMIN EXTENDED RELEASE COMPARED WITH THE FREE COMBINATIONS IN HEALTHY VOLUNTEERS

被引：0
|
作者：
Lippert, C. [1 ]
Sennewald, R. [1 ]
Bell, J. [2 ]
Wiebe, S. [1 ]
Huettner, S. [1 ]
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[2] Boehringer Ingelheim Ltd, Bracknell, Berks, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-001
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [1] PHARMACOKINETICS OF FIXED DOSE COMBINATION (FDC) TABLETS OF LINAGLIPTIN/METFORMIN EXTENDED RELEASE COMPARED WITH THE FREE COMBINATIONS IN HEALTHY VOLUNTEERS.
    Norman, P.
    Lippert, C.
    Hummel, N.
    Hunt, T.
    Huettner, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S46 - S46
  • [2] BIOEQUIVALENCE OF FIXED DOSE COMBINATION (FDC) TABLETS OF EMPAGLIFLOZIN/METFORMIN EXTENDED RELEASE COMPARED WITH THE FREE COMBINATIONS IN HEALTHY VOLUNTEERS.
    Lippert, C.
    Sennewald, R.
    Elsasser, U.
    Huettner, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S74 - S74
  • [3] Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects
    He, Y-L.
    Paladini, S.
    Sabia, H.
    Campestrini, J.
    Zhan, Y.
    Leon, S.
    Ligueros-Saylan, M.
    Jarugula, V.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2008, 46 (05) : 259 - 267
  • [4] Bioequivalence and food effect assessment for vildagliptin/metformin fixed-dose combination tablets relative to free combinations of vildagliptin and metformin in Japanese healthy subjects
    Mita, Sachiko
    Chitnis, Shripad D.
    Kulmatycki, Kenneth
    Salunke, Atish
    Het, Yan-Ling
    Zhou, Wei
    Suzuki, Hikoe
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (04) : 305 - 314
  • [5] Bioequivalence (BE) of Saxagliptin (SAXA)/Dapagliflozin (DAPA) Fixed Dose Combination (FDC) Tablets Compared with Coadministration of the Individual Tablets
    Vakkalagadda, Blisse
    Vetter, Marion
    Rana, Jignasa
    Smith, Charles H.
    Haung, Jian
    Karkas, Jennifer
    Boulton, David W.
    Lacreta, Frank
    DIABETES, 2015, 64 : A325 - A325
  • [6] Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects
    Boulton, David W.
    Smith, Charles H.
    Li, L.
    Huang, Jian
    Tang, Angela
    LaCreta, Frank P.
    CLINICAL DRUG INVESTIGATION, 2011, 31 (09) : 619 - 630
  • [7] Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects
    David W. Boulton
    Charles H. Smith
    L. Li
    Jian Huang
    Angela Tang
    Frank P. LaCreta
    Clinical Drug Investigation, 2011, 31 : 619 - 630
  • [8] Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects
    Boulton, David W.
    Chang, Ming
    Griffen, Steven C.
    Kitaura, Catia
    Lubin, Susan
    Pollack, Allyson
    LaCreta, Frank
    CLINICAL THERAPEUTICS, 2016, 38 (01) : 99 - 109
  • [9] Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Chinese Subjects
    Anders Gummesson
    Haiyan Li
    Michael Gillen
    John Xu
    Mohammad Niazi
    Boaz Hirshberg
    Clinical Drug Investigation, 2014, 34 : 763 - 772
  • [10] Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Chinese Subjects
    Gummesson, Anders
    Li, Haiyan
    Gillen, Michael
    Xu, John
    Niazi, Mohammad
    Hirshberg, Boaz
    CLINICAL DRUG INVESTIGATION, 2014, 34 (11) : 763 - 772
12345